سعر افاستين 400مجم/16مل فيال 2024

Bevacizumab 400 mg/16 ml (25 mg/ml) concentrate for solution for intravenous infusion, 1 single-dose vial; recombinant humanised anti-VEGF monoclonal antibody (Roche).

• Metastatic colorectal cancer, first- or second-line with intravenous fluorouracil-based chemotherapy, or second-line with fluoropyrimidine-irinotecan or -oxaliplatin chemotherapy after progression on a first-line bevacizumab regimen (not for adjuvant colon cancer)Population: AdultsDailyMed (U.S. National Library of Medicine)
• First-line unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, with carboplatin and paclitaxelPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Recurrent glioblastomaPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>10%): epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis; Avastin was discontinued for adverse reactions in 8-22% of patients across studies.International label, same product · DailyMed (U.S. National Library of Medicine)
• Postmarketing: polyserositis, pulmonary hypertension, mesenteric venous occlusion, gastrointestinal ulcer and intestinal necrosis, pancytopenia, gallbladder perforation, osteonecrosis of the jaw, renal thrombotic microangiopathy, nasal septum perforation, arterial aneurysms, dissections and rupture.International label, same product · DailyMed (U.S. National Library of Medicine)

• None (the US label lists no contraindications).International label, same product · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to bevacizumab or any excipient; hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant human or humanised antibodies; pregnancy.International label, same product · European Medicines Agency (EMA)

• Gastrointestinal perforation and fistulae (sometimes fatal; 0.3-3% perforation): discontinue for GI perforation, tracheoesophageal fistula, any grade 4 fistula or fistula involving an internal organ; avoid in ovarian cancer with recto-sigmoid or bowel involvement or bowel obstruction.International label, same product · DailyMed (U.S. National Library of Medicine)
• Surgery and wound-healing complications: withhold at least 28 days before elective surgery, do not give for at least 28 days after major surgery and until the wound has healed; discontinue for necrotizing fasciitis.International label, same product · DailyMed (U.S. National Library of Medicine)
• Hemorrhage, including serious or fatal pulmonary hemorrhage/hemoptysis, GI, CNS and vaginal bleeding: do not give to patients with recent hemoptysis (2.5 mL or more); discontinue for grade 3-4 hemorrhage.International label, same product · DailyMed (U.S. National Library of Medicine)

• Irinotecan (SN38), interferon alfa, carboplatin, paclitaxelNo clinically meaningful effect of bevacizumab on the pharmacokinetics of these drugs was observed; 3 of 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel exposure after four cycles.DailyMed (U.S. National Library of Medicine)

• May cause fetal harm based on animal studies and mechanism of action (malformations in rabbits at doses similar to the clinical dose); advise pregnant women of the risk; females of reproductive potential should use effective contraception during treatment and for 6 months after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)
• Contraindicated in pregnancy: bevacizumab is suspected to cause serious birth defects; women of childbearing potential must use effective contraception during and up to 6 months after treatment.International label, same product · European Medicines Agency (EMA)
• Advise women not to breastfeed during treatment and for 6 months after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Bevacizumab: Binds VEGF and prevents its interaction with its receptors (Flt-1 and KDR) on endothelial cells, inhibiting endothelial proliferation and new blood vessel formation.